CHOI JUNG PILL – Trademark Portfolio
Entity Type: 01
CHOI JUNG PILL owns a portfolio of 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as ODODOS, METABREA, and THE OTHER MAN. Of these, 9 are registered. The portfolio spans 5 Nice Classification classes, led by Class 25 (Clothing) and Class 35 (Advertising & Business). Headquartered in Guangzhou,Guangdong.
Room 2401, Building B10,JinYuLanWan,
JinShaZhou,Baiyun District
Guangzhou,Guangdong 510000 , CN
Showing of trademarks Trademarks
Trademark Classifications
CHOI JUNG PILL's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Carpets, rugs, mats and matting, linoleum and other materials for covering floors
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Leather and imitations of leather; animal skins, hides; trunks and travelling bags
Frequently Asked Questions
How many trademarks does CHOI JUNG PILL have?
CHOI JUNG PILL has 11 U.S. trademarks filed with the USPTO. Of these, 9 registered, 2 abandoned.
What trademark classes does CHOI JUNG PILL file in?
CHOI JUNG PILL files trademarks across 5 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 35 (Advertising & Business), Class 27 (Floor Coverings), Class 9 (Computers & Electronics), Class 18 (Leather Goods). Class 25 covers clothing, footwear, headgear.
What are CHOI JUNG PILL's most well-known trademarks?
CHOI JUNG PILL's registered trademark portfolio includes well-known marks such as ODODOS, METABREA, and THE OTHER MAN. These are among 9 currently registered trademarks in the portfolio.
What is CHOI JUNG PILL's trademark registration success rate?
CHOI JUNG PILL has a 82% trademark registration rate, with 9 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.